PEPTIDES & PROTEINS
elicited a specific immune response and demonstrated unexpected immunogenicity .
Further studies showed that the RNF10 uPeptide could enhance immune function and exert antitumour activity in mice , leading to smaller tumour sizes . The potential of RNF10 uPeptide as an immunotherapeutic agent was also explored in human cells and tumours , with promising results observed in pancreatic cancer and patient-derived tumour xenograft models .
While the study has limitations , including a lack of clinical data , it provides valuable insights into the anti-tumour activity associated with RNF10 uORF and the translated neoantigen peptide . These findings offer new perspectives for future immunotherapeutic drug development and contribute to the identification and validation of more immunogenic neoantigens .
Normal cell
Current progress
While the majority of neoantigen peptide research remains in the pre-clinical stage , several clinical studies and trials are underway to evaluate the efficacy of neoantigenbased immunotherapy in pancreatic cancer . These studies involve the identification of patient-specific neoantigens , the development of personalised vaccines or adoptive T cell therapies targeting neoantigens , and the assessment of their safety and efficacy in clinical settings ( Figure 3 ).
Preliminary results from early-phase clinical trials have shown promising outcomes , including evidence of neoantigen-specific immune responses and potential clinical benefits in subsets of patients . These findings provide a strong rationale for further exploration and optimisation of neoantigen-based immunotherapy approaches in pancreatic cancer .
Tumour cell
0
IFN-y o 0
0 0 0
0
TCR
0
Future prospects
The development of neoantigenbased immunotherapy holds great promise for transforming the treatment landscape of pancreatic cancer . As our understanding of neoantigens and their interactions with the immune system continues to advance , there is an opportunity to refine and optimise neoantigen-based immunotherapeutic strategies .
Furthermore , the integration of neoantigen-based immunotherapy with existing treatment modalities such as chemotherapy , radiation , and immune checkpoint inhibitors may offer synergistic effects and improved clinical outcomes for patients with pancreatic cancer . The future implications of this extend beyond pancreatic cancer , with potential applications in other malignancies and the potential to revolutionise personalised cancer treatment .
The exploration of neoantigen peptides for novel immunotherapy in represents a promising avenue for improving patient outcomes pancreatic cancer . While significant challenges exist , the potential of neoantigen-based immunotherapy to elicit potent and specific antitumour immune responses offers hope for addressing unmet clinical needs . Continued research , clinical development and refinement of neoantigen-based immunotherapy approaches are essential for realising the full potential of this innovative treatment modality . ●
Vaccine
DC
Figure 2 - Unexpected immunogenicity & anti-tumour Activity of RNF10 uPeptide
T cell
Note : Adapted from reference 2 . Retrieved from https :// www . cell . com / molecular-therapy-family / oncolytics / fulltext / S2372- 7705 ( 23 ) 00086-4
References : 1 : X . -J . Han et al ., Frontiers in Cell & Developmental Biology , 2020 , 8 728 2 : L . Zeng et al ., Molecular Therapy-Oncolytics 2023
Guotao Li
DIRECTOR OF PEPTIDE R & D
GENSCRIPT BIOTECH k + 86 159 8666 4197 J gordon . li @ genscript . com j www . genscript . com
MAR / APR 2024 SPECCHEMONLINE . COM
53